[New Service Announcement] Launch of Paraneoplastic Neurological Syndrome-Related Antibody Detection Set (Research Use Only)

~ Cutting-edge technology enables simultaneous testing for 39 types of antibodies ~

Proteo-Bridge Inc. (Head Office: Koto-ku, Tokyo; CEO: Ryo Kumagai), in collaboration with Fushimi Pharmaceutical Co., Ltd., is pleased to announce the launch of a new contract analysis service for autoantibodies related to paraneoplastic neurological syndromes, starting June 18, 2025.

We sincerely invite all medical professionals and researchers to make use of this service.

[Key Features of the New Service]

• Utilization of Protein Array Technology: High-precision analysis using the same technology as our research-use testing service “A-Cube®.”
• Simultaneous Detection of 39 Antibodies: In addition to conventional insurance-covered tests, this service includes a comprehensive analysis of multiple paraneoplastic neurological syndrome-related autoantibodies newly identified through recent research.

This service is intended for use by medical and research institutions involved in paraneoplastic neurological syndromes. It is not available for direct use by the general public. Please consult your physician for more information.
Please note that this is a research-use only test and cannot be used for diagnostic purposes.

 ※Please note that this procedure is intended for use only in Japan.

[Contact Information for Test Service Inquiries]

• Company: Fushimi Pharmaceutical Co., Ltd., Hygiene Testing Center
• Phone: +81-877-22-6276
• E-mail: th＊fushimi.co.jp
  (*Please replace the asterisk with @)

[Intellectual Property Licensor]

• Company: Proteo-Bridge Inc.
• Phone: +81-3-6457-1661 (Contract Testing Division)
• E-mail: kensa＊proteo-bridge.co.jp
  (*Please replace the asterisk with @)

For more details on this product, please visit our official website or contact our Public Relations team.

[Inquiries Regarding This Announcement]

Public Relations, Proteo-Bridge Inc.
E-mail: sato＊proteo-bridge.co.jp
(*Please replace the asterisk with @)